Is Novocure Ltd (nvcr) a great growth stock?
NVCR ranks lowest in Growth; there it ranks in the 4th percentile. Price to trailing twelve month operating cash flow for NVCR is currently 106.65, higher than 95.92% of US stocks with positive operating cash flow. With a price/sales ratio of 16.5, NovoCure Ltd has a higher such ratio than 91.38% of stocks in our set.
Is nvcr's stock trending up or down?
NVCR's strongest trending metric is Momentum; it's been moving down over the last 179 days. NVCR ranks lowest in Growth; there it ranks in the 4th percentile. Price to trailing twelve month operating cash flow for NVCR is currently 106.65, higher than 95.92% of US stocks with positive operating cash flow.
Is nvcr a great medical equipment stock to buy?
NVCR has a Quality Grade of B, ranking ahead of 83.73% of graded US stocks. NVCR's asset turnover comes in at 0.503 -- ranking 92nd of 186 Medical Equipment stocks. IDXG, HAE, and CTSO are the stocks whose asset turnover ratios are most correlated with NVCR.
Will Novocure (nvcr) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. Vote “Outperform” if you believe NVCR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
See more
Is NVCR stock a good buy?
Out of 8 analysts, 3 (37.5%) are recommending NVCR as a Strong Buy, 2 (25%) are recommending NVCR as a Buy, 2 (25%) are recommending NVCR as a Hold, 1 (12.5%) are recommending NVCR as a Sell, and 0 (0%) are recommending NVCR as a Strong Sell.
Will NovoCure go up?
The 8 analysts offering 12-month price forecasts for Novocure Ltd have a median target of 95.50, with a high estimate of 200.00 and a low estimate of 45.00. The median estimate represents a +31.76% increase from the last price of 72.48.
Does NovoCure pay a dividend?
Novocure (NASDAQ: NVCR) does not pay a dividend.
Is NovoCure a public company?
NovoCure Limited has applied to list its common stock on the NASDAQ Global Select Market under the symbol “NVCR.”
What is happening with NovoCure?
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates NovoCure (NVCR) delivered earnings and revenue surprises of 76.47% and 1.25%, respectively, for the quarter ended March 2022.
Who are NovoCure competitors?
NovoCure's top competitors include Lyell, Silverback Therapeutics, Sensei Biotherapeutics, Accuray, Zymeworks and Legend Biotech. NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
Is NovoCure FDA approved?
HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for its LUNAR trial to 276 patients with 12 months follow-up.
How big is NovoCure?
Palti's initial research from his basement laboratory evolved to become Novocure – an international oncology company with more than 1,000 employees and operations in North America, Europe, the Middle East and Asia.
Recently Viewed Tickers
Novocure Ltd
Visit a quote page and your recently viewed tickers will be displayed here.
How much does Novocure make?
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Is Novocure a hold?
NovoCure has a market capitalization of $19.58 billion and generates $494.37 million in revenue each year. The medical equipment provider earns $19.81 million in net income (profit) each year or $0.18 on an earnings per share basis.
Nasdaq Global Select
Wall Street analysts have given NovoCure a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NovoCure wasn't one of them.
Environmental, Social, and Governance Rating
Novocures tumor-treating field devices use electric fields to disrupt the replication of cancer cells.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Key Earnings Data
Novocures tumor-treating field devices use electric fields to disrupt the replication of cancer cells.
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
What is the strongest trend for NVCR?
Rhenman & Partners Asset Management AB Buys Boston Scientific Corp, Alnylam Pharmaceuticals ...
Where is NovoCure located?
The strongest trend for NVCR is in Growth, which has been heading down over the past 31 weeks. NVCR's current lowest rank is in the Sentiment metric (where it is better than 5.48% of US stocks).
Sales
- Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, May, 2nd. The medical equipment provider reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13). The medical equipment provider had revenue of $73.31 million for the quarter, compared to analyst estimates of $72.85 million. N...
Release
- Novocure is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Novocure.
Risks
- 7 equities research analysts have issued 12 month price objectives for Novocure's shares. Their forecasts range from $36.00 to $63.00. On average, they anticipate Novocure's share price to reach $48.7143 in the next year. This suggests that the stock has a possible downside of 1.2%. View Analyst Price Targets for Novocure.
Ratings
- 7 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Novocure in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Novocure.
Reception
- Media stories about NVCR stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the mos…
Ownership
- Novocure's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (8.41%), BlackRock Inc. (5.02%), Wells Fargo & Company MN (1.10%), TimesSquare Capital Management LLC (1.03%), Rhenman & Partners Asset Management AB (0.48%) and Frontier Capital Management Co. LLC (0.38%). Company insiders t…
Business
- Novocure has a market capitalization of $4.72 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.